Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
Status:
Withdrawn
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and maximum tolerated dose of inhaled
NX1011 for the treatment of pulmonary arterial hypertension (PAH).